The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models.
 
Roberto Ferrara
No Relationships to Disclose
 
Giuseppe Lo Russo
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD
 
Diego Signorelli
No Relationships to Disclose
 
Claudia Proto
No Relationships to Disclose
 
Arsela Prelaj
No Relationships to Disclose
 
Giulia Galli
No Relationships to Disclose
 
Alessandro De Toma
No Relationships to Disclose
 
Giuseppe Viscardi
No Relationships to Disclose
 
Riccardo Lobefaro
No Relationships to Disclose
 
Marta Brambilla
No Relationships to Disclose
 
Giovanna Talarico
No Relationships to Disclose
 
Barbara Bassani
No Relationships to Disclose
 
Sestina Maria Spanò
No Relationships to Disclose
 
Giuliano Molino
No Relationships to Disclose
 
Nicoletta Zilembo
No Relationships to Disclose
 
Monica Ganzinelli
No Relationships to Disclose
 
Stefania Vitale
No Relationships to Disclose
 
Mario Paolo Colombo
No Relationships to Disclose
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Incyte; Inivata; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Sabina Sangaletti
No Relationships to Disclose